471 related articles for article (PubMed ID: 30395718)
1. Management of fibrolamellar hepatocellular carcinoma.
Chaudhari VA; Khobragade K; Bhandare M; Shrikhande SV
Chin Clin Oncol; 2018 Oct; 7(5):51. PubMed ID: 30395718
[TBL] [Abstract][Full Text] [Related]
2. Fibrolamellar hepatocellular carcinoma.
Liu S; Chan KW; Wang B; Qiao L
Am J Gastroenterol; 2009 Oct; 104(10):2617-24; quiz 2625. PubMed ID: 19638962
[TBL] [Abstract][Full Text] [Related]
3. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments.
Kassahun WT
World J Surg Oncol; 2016 May; 14(1):151. PubMed ID: 27215576
[TBL] [Abstract][Full Text] [Related]
4. Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Okur A; Eser EP; Yilmaz G; Dalgiç A; Akdemir ÜÖ; Oğuz A; Karadeniz C; Akyol G; Demiroğullari B; Boyunağa Ö; Pinarli FG
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e328-32. PubMed ID: 24608073
[TBL] [Abstract][Full Text] [Related]
5. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma.
Zenali MJ; Tan D; Li W; Dhingra S; Brown RE
Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623
[TBL] [Abstract][Full Text] [Related]
6. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
Abdelhamed W; El-Kassas M
World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
[TBL] [Abstract][Full Text] [Related]
8. Imaging findings of fibrolamellar hepatocellular carcinomas on ultrasonography: A comparison with conventional hepatocellular carcinomas.
Fu T; Ding H; Xu C; Zhu Y; Xue L; Lin F
Clin Hemorheol Microcirc; 2021; 77(1):49-60. PubMed ID: 32924993
[TBL] [Abstract][Full Text] [Related]
9. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation.
McLarney JK; Rucker PT; Bender GN; Goodman ZD; Kashitani N; Ros PR
Radiographics; 1999; 19(2):453-71. PubMed ID: 10194790
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle biology of fibrolamellar hepatocellular carcinoma.
Dhingra S; Li W; Tan D; Zenali M; Zhang H; Brown RE
Int J Clin Exp Pathol; 2010 Nov; 3(8):792-7. PubMed ID: 21151393
[TBL] [Abstract][Full Text] [Related]
11. [Surgical therapy of hepatic fibrolamellar carcinoma].
Meriggi F; Forni E
Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
[TBL] [Abstract][Full Text] [Related]
12. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis.
Yu JH; Kim JM; Kim JK; Choi SJ; Lee KS; Lee JW; Chang HY; Lee JI
Oncotarget; 2017 Jun; 8(24):39534-39546. PubMed ID: 28465473
[TBL] [Abstract][Full Text] [Related]
13. [Fibrolamellar carcinoma of the liver: hepatocellular carcinoma with favourable prognosis].
Denis J; Grippon P; Legendre C; Tubiana JM; Lévy VG
Gastroenterol Clin Biol; 1984 Dec; 8(12):920-4. PubMed ID: 6097494
[TBL] [Abstract][Full Text] [Related]
14. Case report: fibrolamellar hepatocellular carcinoma in a Japanese woman: a case report and review of Japanese cases.
Hoshino H; Katada N; Nishimura D; Imada J; Morita K; Yoshida N; Sano H; Okamoto K; Kato K
J Gastroenterol Hepatol; 1996 Jun; 11(6):551-5. PubMed ID: 8792309
[TBL] [Abstract][Full Text] [Related]
15. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.
Mayo SC; Mavros MN; Nathan H; Cosgrove D; Herman JM; Kamel I; Anders RA; Pawlik TM
J Am Coll Surg; 2014 Feb; 218(2):196-205. PubMed ID: 24315886
[TBL] [Abstract][Full Text] [Related]
16. [Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis--retrospective study].
Witjes CD; de Man RA; Eskens FA; Dwarkasing RS; Zondervan PE; Verhoef C; Ijzermans JN
Ned Tijdschr Geneeskd; 2010; 154():A1747. PubMed ID: 20719013
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma.
Li W; Tan D; Zenali MJ; Brown RE
Int J Clin Exp Pathol; 2009 Jan; 3(3):238-43. PubMed ID: 20224721
[TBL] [Abstract][Full Text] [Related]
18. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour.
Vasdev N; Nayak NC
Indian J Pathol Microbiol; 2003 Oct; 46(4):625-9. PubMed ID: 15025359
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with fibrolamellar hepatocellular carcinoma.
Stipa F; Yoon SS; Liau KH; Fong Y; Jarnagin WR; D'Angelica M; Abou-Alfa G; Blumgart LH; DeMatteo RP
Cancer; 2006 Mar; 106(6):1331-8. PubMed ID: 16475212
[TBL] [Abstract][Full Text] [Related]
20. Natural history and treatment trends in hepatocellular carcinoma subtypes: Insights from a national cancer registry.
Jernigan PL; Wima K; Hanseman DJ; Hoehn RS; Ahmad SA; Shah SA; Abbott DE
J Surg Oncol; 2015 Dec; 112(8):872-6. PubMed ID: 26603598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
